This review maps the diabetes-kidney-heart continuum — how type 2 diabetes progressively damages blood vessels, kidneys, and the heart — and highlights GLP-1 receptor agonists and SGLT2 inhibitors as therapies that protect multiple organs simultaneously.
3-stage frameworkThe prevent-regress-retard model for managing the diabetes-kidney-heart continuum, guiding when and how to intervene with cardio-renal protective therapies
What the researchers found
The review outlines a framework for understanding and managing the diabetes-kidney-heart continuum through three stages:
1. **Prevent**: Early risk stratification and intervention before vascular damage occurs
2. **Regress**: Reversing early vascular changes when detected
3. **Retard**: Slowing progression of established cardiovascular and kidney disease
Key therapeutic classes for managing this continuum include SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, lipid-lowering therapy, and RAAS blockers — all with evidence for both cardiac and renal protection. New diagnostic biomarkers (BNP, NT-proBNP, cardiac troponin, cystatin C) and technologies (single-cell transcriptome sequencing) can detect vascular complications earlier than traditional methods.
Why it matters
Heart disease and kidney disease are the leading causes of death in people with type 2 diabetes, and they often develop together. Treating them as separate conditions misses the interconnected nature of the damage. This continuum framework helps clinicians think about diabetes complications holistically and choose therapies — like GLP-1 receptor agonists and SGLT2 inhibitors — that protect multiple organs at once, rather than treating each complication in isolation.
How the study worked
This is a narrative review synthesizing evidence on the pathophysiology, diagnosis, and management of vascular complications in type 2 diabetes, organized around the concept of a diabetes-kidney-heart continuum. The authors reviewed pharmacotherapy evidence for each drug class and summarized emerging diagnostic approaches.
What this study cannot tell us
This is a narrative review, which may be subject to selection bias in the literature chosen. It does not present new primary data or conduct systematic analysis with predefined inclusion criteria. The three-stage framework (prevent, regress, retard) is conceptual and may oversimplify the complex, non-linear progression of diabetic complications. The review does not address cost-effectiveness or access barriers for the therapies discussed.
How to read the evidence
This is a narrative review article that synthesizes existing clinical trial data and guidelines. While it references high-quality evidence from landmark trials of GLP-1 RAs and SGLT2 inhibitors, the review itself is a secondary source providing expert synthesis and a conceptual framework.
When this study was published
Published in 2025, this review incorporates the latest evidence from major cardiovascular and renal outcome trials for GLP-1 receptor agonists and SGLT2 inhibitors.
The bigger picture
The concept of a diabetes-kidney-heart continuum reflects a paradigm shift in how clinicians approach type 2 diabetes. Rather than treating hyperglycemia as the primary target, modern management increasingly focuses on preventing organ damage. The emergence of GLP-1 receptor agonists and SGLT2 inhibitors — drugs that lower blood sugar while also protecting the heart and kidneys — has fundamentally changed the treatment algorithm for type 2 diabetes.
Questions still open
- Can the combination of GLP-1 receptor agonists and SGLT2 inhibitors provide additive cardio-renal protection beyond either drug alone?
- How can the proposed biomarkers (BNP, cystatin C, troponin) be practically integrated into routine diabetes care for earlier detection?
- What is the optimal timing for initiating cardio-renal protective therapies — should all newly diagnosed type 2 diabetes patients start them immediately?
Common questions
Why does diabetes damage both the heart and kidneys?
What makes GLP-1 drugs and SGLT2 inhibitors special for diabetes patients?
Read the original research
Diabetes-Kidney-Heart Continuum and Its Implication on Therapeutic Management.
Cureus, 17(7), e88561
Citation
Zargar, Abdul Hamid; Balagopalan, Jayagopal Pathiyil; Bhattacharyya, Arpandev; Almeida, Alan; Taraphder, Abhijit; Bansal, Sandeep; Dani, Sameer; Deka, Nilakshi; Jain, Sanjay; Swami, Onkar C. (2025). Diabetes-Kidney-Heart Continuum and Its Implication on Therapeutic Management.. Cureus, 17(7), e88561. https://doi.org/10.7759/cureus.88561